Cargando…

The Noradrenergic System in Parkinson’s Disease

Nowadays it is well accepted that in Parkinson’s disease (PD), the neurodegenerative process occurs in stages and that damage to other areas precedes the neuronal loss in the substantia nigra pars compacta, which is considered a pathophysiological hallmark of PD. This heterogeneous and progressive n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paredes-Rodriguez, Elena, Vegas-Suarez, Sergio, Morera-Herreras, Teresa, De Deurwaerdere, Philippe, Miguelez, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157437/ https://www.ncbi.nlm.nih.gov/pubmed/32322208 http://dx.doi.org/10.3389/fphar.2020.00435

Ejemplares similares

Editorial: Non-Dopaminergic Systems in Parkinson’s Disease
por: Miguelez, Cristina, et al.
Publicado: (2020)

Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation
por: Vegas-Suárez, Sergio, et al.
Publicado: (2022)

Endocannabinoid Modulation of Dopaminergic Motor Circuits
por: Morera-Herreras, Teresa, et al.
Publicado: (2012)

Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease
por: Miguelez, Cristina, et al.
Publicado: (2014)

Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex
por: Devoto, Paola, et al.
Publicado: (2020)

The involvement of the noradrenergic system in the antinociceptive effect of cucurbitacin D on mice with paclitaxel-induced neuropathic pain
por: Park, Keun-Tae, et al.
Publicado: (2023)

Selective Vulnerability of the Locus Coeruleus Noradrenergic System and its Role in Modulation of Neuroinflammation, Cognition, and Neurodegeneration
por: Evans, Andrew K., et al.
Publicado: (2022)

Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease
por: Buddhala, Chandana, et al.
Publicado: (2015)

Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers
por: Requejo, Catalina, et al.
Publicado: (2020)

Combined α(2)- and D(2)-receptor blockade activates noradrenergic and dopaminergic neurons, but extracellular dopamine in the prefrontal cortex is determined by uptake and release from noradrenergic terminals
por: Sagheddu, Claudia, et al.
Publicado: (2023)

Rescue of Noradrenergic System as a Novel Pharmacological Strategy in the Treatment of Chronic Pain: Focus on Microglia Activation
por: Caraci, Filippo, et al.
Publicado: (2019)

Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain
por: Di Giovanni, Giuseppe, et al.
Publicado: (2020)

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
por: Miguelez, Cristina, et al.
Publicado: (2017)

Noradrenaline and Parkinson's Disease
por: Delaville, Claire, et al.
Publicado: (2011)

Editorial: Contemporary Perspective on 5-HT(2C) Receptor Function and Its Pharmacological Targeting
por: De Deurwaerdère, Philippe, et al.
Publicado: (2020)

Dying-back of ascending noradrenergic projections in Parkinson’s disease
por: Helmich, Rick C, et al.
Publicado: (2021)

Restoration of Noradrenergic Function in Parkinson’s Disease Model Mice
por: Cui, Kui, et al.
Publicado: (2021)

Targeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson's disease
por: O’Neill, Eoin, et al.
Publicado: (2018)

Editorial: Insights on neuroinflammatory response by microglia-targeted pharmacology
por: Raber, Jacob, et al.
Publicado: (2023)

Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies
por: Peterson, Andrew C., et al.
Publicado: (2018)

Biphasic Effects of α-Asarone on Immobility in the Tail Suspension Test: Evidence for the Involvement of the Noradrenergic and Serotonergic Systems in Its Antidepressant-Like Activity
por: Chellian, Ranjithkumar, et al.
Publicado: (2016)

Contributions of the Nucleus Accumbens Shell in Mediating the Enhancement in Memory Following Noradrenergic Activation of Either the Amygdala or Hippocampus
por: Kerfoot, Erin C., et al.
Publicado: (2018)

α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis
por: Butkovich, Laura M., et al.
Publicado: (2018)

Shining light on the noradrenergic system
por: Tanguay, Emmeraude, et al.
Publicado: (2023)

Sequential Loss of LC Noradrenergic and Dopaminergic Neurons Results in a Correlation of Dopaminergic Neuronal Number to Striatal Dopamine Concentration
por: Szot, Patricia, et al.
Publicado: (2012)

Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease
por: Chagraoui, Abdeslam, et al.
Publicado: (2022)

Noradrenergic deficits contribute to apathy in Parkinson’s disease through the precision of expected outcomes
por: Hezemans, Frank H., et al.
Publicado: (2022)

The acute and long‐term L‐DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6‐OHDA lesioned rats
por: Miguelez, C, et al.
Publicado: (2016)

Noradrenergic dysfunction in Alzheimer's disease
por: Gannon, Mary, et al.
Publicado: (2015)

Modelling the dopamine and noradrenergic cell loss that occurs in Parkinson's disease and the impact on hippocampal neurogenesis
por: Ermine, Charlotte M., et al.
Publicado: (2018)

Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration
por: Aristieta, A., et al.
Publicado: (2013)

The effect of 5‐HT(1A) receptor agonists on the entopeduncular nucleus is modified in 6‐hydroxydopamine‐lesioned rats
por: Vegas‐Suárez, Sergio, et al.
Publicado: (2021)

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
por: Chagraoui, Abdeslam, et al.
Publicado: (2019)

Noradrenergic Modulation of Cognition in Health and Disease
por: Borodovitsyna, Olga, et al.
Publicado: (2017)

Noradrenergic therapies for apathy in Alzheimer’s disease?
por: Husain, Masud
Publicado: (2023)

Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism
por: Kreiner, Grzegorz, et al.
Publicado: (2019)

Chinese Herbal Medicine in the Treatment of Depression in Parkinson’s Disease: From Molecules to Systems
por: Zhang, Yi, et al.
Publicado: (2022)

Modulating arousal to overcome gait impairments in Parkinson’s disease: how the noradrenergic system may act as a double-edged sword
por: Tosserams, Anouk, et al.
Publicado: (2023)

Sleep Disorders in Rodent Models of Parkinson’s Disease
por: Medeiros, Daniel de Castro, et al.
Publicado: (2019)

Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease
por: Cao, Lei-Fang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7ikldiki17i0c61p0n4mpodn4h